Haemonetics Corporation
HAE
$81.35
$0.600.74%
NYSE
| 09/27/2025 | 06/28/2025 | 03/29/2025 | 12/28/2024 | 09/28/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.33B | 1.35B | 1.36B | 1.37B | 1.36B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.33B | 1.35B | 1.36B | 1.37B | 1.36B |
| Cost of Revenue | 542.31M | 563.91M | 591.26M | 614.16M | 616.86M |
| Gross Profit | 785.54M | 782.14M | 769.57M | 759.35M | 744.37M |
| SG&A Expenses | 422.48M | 427.42M | 428.85M | 427.28M | 427.65M |
| Depreciation & Amortization | 46.10M | 47.18M | 48.26M | 47.39M | 42.07M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.07B | 1.10B | 1.13B | 1.15B | 1.14B |
| Operating Income | 256.71M | 247.68M | 233.72M | 226.25M | 219.13M |
| Income Before Tax | 217.11M | 210.53M | 212.07M | 164.75M | 158.86M |
| Income Tax Expenses | 48.92M | 47.19M | 44.39M | 34.68M | 35.05M |
| Earnings from Continuing Operations | 168.19 | 163.34 | 167.68 | 130.07 | 123.81 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 168.19M | 163.34M | 167.68M | 130.07M | 123.81M |
| EBIT | 256.71M | 247.68M | 233.72M | 226.25M | 219.13M |
| EBITDA | 364.26M | 356.18M | 342.60M | 332.67M | 320.06M |
| EPS Basic | 3.44 | 3.30 | 3.34 | 2.56 | 2.43 |
| Normalized Basic EPS | 2.80 | 2.64 | 2.62 | 2.59 | 2.59 |
| EPS Diluted | 3.43 | 3.28 | 3.32 | 2.54 | 2.41 |
| Normalized Diluted EPS | 2.79 | 2.63 | 2.60 | 2.57 | 2.56 |
| Average Basic Shares Outstanding | 195.18M | 198.49M | 201.32M | 202.91M | 203.40M |
| Average Diluted Shares Outstanding | 196.13M | 199.71M | 202.92M | 204.85M | 205.66M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |